Citations

Mayo Clinic

Showing 10 of 108522 citations.

Extensive acute axonal damage in pediatric multiple sclerosis lesions
Pfeifenbring, Sabine, Bunyan, Reem F., Metz, Imke , Röver, Christian , Gärtner, Jutta , Lucchinetti, Claudia F. , Brück, Wolfgang , Huppke, Peter

Annals of Neurology | January 21, 2015 | Volume: 77 | Issue: 4 | Pages: 655-667

10.1002/ana.24364 | PMID 25612167 Get It

ObjectiveAxonal damage occurs early in multiple sclerosis (MS) and contributes to the degree of clinical disability. Children with MS more often show disabling and polyfocal neurological symptoms at disease onset than adults with MS. Thus, axonal damage may differ between pediatric and adult MS patients.MethodsWe analyzed axonal pathology in archival brain biopsy and autopsy samples from 19 children with early MS. Lesions were classified according to demyelinating activity and presence of remyelination. Axonal density and extent of acute axonal damage were assessed using Bielschowsky silver impregnation and immunohistochemistry for amyloid precursor protein (APP), respectively. Axonal injury was correlated with the inflammatory infiltrate as well as clinical characteristics. Results were compared with data from adult MS patients.ResultsAcute axonal damage was most extensive in early active demyelinating (EA) lesions of pediatric patients and correlated positively with the Expanded Disability Status Scale at attack leading to biopsy/autopsy. Comparison with 12 adult patients showed a 50% increase in the extent of acute axonal damage in EA lesions from children compared to adults, with the highest number of APP‐positive spheroids found prior to puberty. The extent of acute axonal damage correlated positively with the number of lesional macrophages. Axonal density was reduced in pediatric lesions irrespective of the demyelinating activity or the presence of remyelination. Axonal reduction was similar between children and adults.InterpretationOur results provide evidence for more pronounced acute axonal damage in inflammatory demyelinating lesions from children compared to adults. Ann Neurol 2015;77:655–667
Ebola virus: Melatonin as a readily available treatment option
Anderson, George , Maes, Michaël , Markus, Regina P. , Rodriguez, Moses , Rodriguez, Moses

Journal of Medical Virology | January 21, 2015 | Volume: 87 | Issue: 4 | Pages: 537-543

10.1002/jmv.24130 | PMID 25611054 Get It

There is currently an urgent need for a viable, cheap, and readily available treatment for the Ebola virus outbreak in West Africa. Here, it is proposed that melatonin may have significant utility in helping the management of this outbreak. Optimizing natural killer (NK) cell responses seems crucial to surviving Ebola virus infection. Melatonin increases NK cell cytotoxicity significantly, suggesting efficacy in managing the Ebola virus. Under conditions of challenge, melatonin increases heme oxygenase‐1 (HO‐1), which inhibits Ebola virus replication. Melatonin also has protective effects in cases of septic shock, which, although bacterial, has similar end‐point presentations involving blood vessel leakage. Melatonin's effects on haemorrhage are mediated primarily by a decrease in pro‐inflammatory cytokines. By optimizing the appropriate immune response, melatonin is likely to afford protection to those at high risk of Ebola viral infection, as well as having direct impacts on the course of infection per se. Although no direct data pertain to the utility of melatonin in the management of the Ebola virus, convergent bodies of data suggest its utility, which is reviewed in this article. J. Med. Virol. 87:537–543, 2015. © 2015 Wiley Periodicals, Inc.
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management
Tefferi, Ayalew , Barbui, Tiziano

American Journal of Hematology | January 21, 2015 | Volume: 90 | Issue: 2 | Pages: 162-173

10.1002/ajh.23895 | PMID 25611051 Get It

Disease overview:Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation.Diagnosis:PV is defined by aJAK2mutation, whose absence, combined with normal or increased serum erythropoietin level, makes the diagnosis unlikely. Differential diagnosis in ET includes reactive thrombocytosis, chronic myeloid leukemia, and prefibrotic myelofibrosis. Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations occur in approximately 55%, 25%, and 3% of ET patients, respectively. The same molecular markers are also present in prefibrotic myelofibrosis, which needs to be morphologically distinguished from ET.Survival and leukemic/fibrotic transformation:Median survivals are ∼14 years for PV and 20 years for ET; the corresponding values for younger patients are 24 and 33 years. Life‐expectancy in ET is inferior to the control population.JAK2/CALRmutational status does not affect survival in ET. Risk factors for survival in ET and PV include advanced age, leukocytosis, and thrombosis. Leukemic transformation rates at 20 years are estimated at <10% for PV and 5% for ET; fibrotic transformation rates are slightly higher.Thrombosis risk stratification:Current risk stratification in PV and ET is designed to estimate the likelihood of recurrent thrombosis: high‐risk is defined by the presence of age >60 years or presence of thrombosis history; low‐risk is defined by the absence of both of these two risk factors. Recent data considerJAK2V617F and cardiovascular risk factors as additional risk factors. Presence of extreme thrombocytosis might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding.Risk‐adapted therapy:The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. In low risk patients, this is accomplished by the use of low‐dose aspirin and phlebotomy (hematocrit target <45%) in PV. In high risk (for thrombosis) patients, treatment with hydroxyurea is additionally recommended. Treatment with busulfan or interferon‐α is usually effective in hydroxyurea failures and the additional value of JAK inhibitor therapy in such cases is limited. Screening for AvWS is recommended before administrating aspirin, in the presence of extreme thrombocytosis. Am. J. Hematol. 90:163–173, 2015. © 2014 Wiley Periodicals, Inc.
Effects of trypsinization and mineralization on intrasynovial tendon allograft healing to bone
Alphen, Nick A. van, Thoreson, Andrew R. , Chen, Qingshan , An, Kai‐Nan, Amadio, Peter C. , Zhao, Chunfeng , Qu, Jin, Qu, Jin , An, Kai‐Nan , Schmid, Thomas M

Journal of Orthopaedic Research | January 21, 2015 | Volume: 33 | Issue: 4 | Pages: 468-474

10.1002/jor.22779 | PMID 25611186 Get It

ABSTRACTThe purpose of the current study was to develop a novel technology to enhance tendon‐to‐bone interface healing by trypsinizing and mineralizing (TM) an intrasynovial tendon allograft in a rabbit bone tunnel model. Eight rabbit flexor digitorum profundus (FDP) tendons were used to optimize the trypsinization process. An additional 24 FDP tendons were stratified into control and TM groups; in each group, 4 tendons were used for in vitro evaluation of TM and 8 were transplanted into proximal tibial bone tunnels in rabbits. The samples were evaluated histologically and with mechanical testing at postoperative week 8. Maximum failure strength and linear stiffness were not significantly different between the control and TM tendons. A thin fibrous band of scar tissue formed at the graft‐to‐bone interface in the control group. However, only the TM group showed obvious new bone formation inside the tendon graft and a visible fibrocartilage layer at the bone tunnel entrance. This study is the first to explore effects of TM on the intrasynovial allograft healing to a bone tunnel. TM showed beneficial effects on chondrogenesis, osteogenesis, and integration of the intrasynovial tendon graft, but mechanical strength was the same as the control tendons in this short‐term in vivo study. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:468–474, 2015.
Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Biomarkers in Medicine | January 21, 2015 | Volume: 9 | Issue: 1 | Pages: 1-3

10.2217/bmm.14.99 | PMID 25605449 Get It

HER2 Testing and its Predictive Utility in Anti-HER2 Breast Cancer Therapy
Advani, Pooja , Crozier, Jennifer A. , Perez, Edith A. , Advani, Pooja P

Biomarkers in Medicine | January 21, 2015 | Volume: 9 | Issue: 1 | Pages: 35-49

10.2217/bmm.14.95 | PMID 25605454 Get It

Internal biliary stenting during orthotopic liver transplantation: anastomotic complications, post‐transplant biliary interventions, and survival
Mathur, Amit K. , Nadig, Satish N. , Kingman, Stephanie, Lee, Dustin , Kinkade, Kathleen, Sonnenday, Christopher J. , Welling, Theodore H.

Clinical Transplantation | January 21, 2015 | Volume: 29 | Issue: 4 | Pages: 327-335

10.1111/ctr.12518 | PMID 25604635 Get It

AbstractBackgroundBiliary complications are a leading source of surgical morbidity following orthotopic liver transplantation (OLT).MethodsWe examined how prophylactic internal biliary stent placement during OLT affected post‐transplant morbidity and mortality in a single‐center retrospective cohort study of 513 recipients (2006–2012). Recipient and donor covariates were collected. Biliary complications included major and minor anastomotic leaks, strictures, or stenoses. Multivariate regression models were created to estimate how operative biliary stents affected outcomes.ResultsAbout 87.3% (n = 448) of recipients had a duct‐to‐duct biliary anastomosis, and 43.1% (n = 221) had biliary stents placed. The biliary complication rate was <15% at five yr, and 44.8% (n = 230) overall. Stenting was not protective from anastomotic biliary complications (p = 0.06). Stenting was associated with a 74% higher adjusted risk of needing multiple endoscopic retrograde cholangiographies (ERCs; odds ratio [OR] 1.74, p = 0.011), and trended toward a lower adjusted risk for repetitive percutaneous transhepatic cholangiography (PTCs; OR 0.56, p = 0.063). Stenting had no effect on the cumulative freedom from biliary complications (p = 0.94). Biliary complications were associated with mortality (HR 1.86, p = 0.014) and was unaffected by stenting (aHR = 0.72, p = 0.246).ConclusionsBiliary stenting during OLT does not deter biliary complications and is associated with higher risk of multiple invasive biliary interventions, particularly ERCs. Surgeons should evaluate the utility of biliary stents at OLT within this context.
Epidemiology of invasive fungal infections in lung transplant recipients on long‐term azole antifungal prophylaxis
Chong, Pearlie P. , Kennedy, Cassie C. , Hathcock, Matthew , Kremers, Walter K. , Razonable, Raymund R. , Kennedy, Cassie C , Kremers, Walter K

Clinical Transplantation | January 21, 2015 | Volume: 29 | Issue: 4 | Pages: 311-318

10.1111/ctr.12516 | PMID 25604399 Get It

AbstractLung transplant recipients (LTR) at our institution receive prolonged and mostly lifelong azole antifungal (AF) prophylaxis. The impact of this prophylactic strategy on the epidemiology and outcome of invasive fungal infections (IFI) is unknown. This was a single‐center, retrospective cohort study. We reviewed the medical records of all adult LTR from January 2002 to December 2011. Overall, 16.5% (15 of 91) of patients who underwent lung transplantation during this time period developed IFI. Nineteen IFI episodes were identified (eight proven, 11 probable), 89% (17 of 19) of which developed during AF prophylaxis. LTR with idiopathic pulmonary fibrosis were more likely to develop IFI (HR: 4.29; 95% CI: 1.15–15.91; p = 0.03). A higher hazard of mortality was observed among those who developed IFI, although this was not statistically significant (hazard ratio [HR]: 1.71; 95% confidence interval [CI] [0.58–4.05]; p = 0.27). Aspergillus fumigatus was the most common cause of IFI (45%), with pulmonary parenchyma being the most common site of infection. None of our patients developed disseminated invasive aspergillosis, cryptococcal or endemic fungal infections. IFI continue to occur in LTR, and the eradication of IFI appears to be challenging even with prolonged prophylaxis. Azole resistance is uncommon despite prolonged AF exposure.
Aspiration during Monitored Anesthesia Care
Bohman, J. Kyle , Bohman, John Kyle, Bohman, John K

Anesthesiology | January 21, 2015 | Volume: 122 | Issue: 2 | Pages: 471-472

10.1097/aln.0000000000000535 | PMID 25603212 Get It

Achalasia and chronic opiate use: innocent bystanders or associated conditions?
Geno, Debra M., Katzka, David A. , Ravi, Karthik , Murray, Joseph A.

Diseases of the Esophagus | January 21, 2015 | Volume: 29 | Issue: 1 | Pages: 15-21

10.1111/dote.12291 | PMID 25604060 Get It